Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Otonomy Inc    OTIC

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/19/2017 06/20/2017 06/21/2017 06/22/2017 06/23/2017 Date
14.9(c) 16.05(c) 17.5(c) 17.75(c) 18.75(c) Last
207 329 404 570 396 798 275 633 697 181 Volume
+2.05% +7.72% +9.03% +1.43% +5.63% Change
More quotes
Financials ($)
Sales 2017 3,36 M
EBIT 2017 -100 M
Net income 2017 -100,0 M
Finance 2017 39,0 M
Yield 2017 -
Sales 2018 16,2 M
EBIT 2018 -95,5 M
Net income 2018 -95,4 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 157x
Capi. / Sales2018 34,9x
Capitalization 567 M
More Financials
Company
Otonomy, Inc. engages in the research, development, and manufacture of biopharmaceutical products.The firm's portfolio includes therapeutics for diseases and disorders of the ear such as otitis media, acute otitis externa, balance disorders, Ménière's disease, tinnitus, cisplatin-induced hearing... 
More about the company
Surperformance© ratings of Otonomy Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on OTONOMY INC
06/23 OTONOMY, INC. (NASDAQ : OTIC) Files An 8-K Submission of Matters to a Vote of Se..
06/23 OTONOMY, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
06/23 OTONOMY : Announces Successful End-of-Phase 2 Review by FDA for OTIPRIO in Acute..
06/22 Otonomy Announces Successful End-of-Phase 2 Review by FDA for OTIPRIO® in Acu..
06/21 OTONOMY : to Host Key Opinion Leader Meeting June 27
06/20 Otonomy to Host Key Opinion Leader Meeting for Investors on Ménière's Disease
06/14 OTONOMY : Federal Contracts Awarded by Federal Agencies in Illinois (June 14)
06/14 OTONOMY : Award Notice - Otonomy, Inc (65IB) Contract Award 10/15/2016 65IB Drug..
06/14 OTONOMY : CONTRACT AWARD - 65-- Otonomy, Inc (65IB) Contract Award 10/15/2016 65..
06/14 OTONOMY : $225,000 Federal Contract Awarded to Otonomy
More news
Sector news : Bio Therapeutic Drugs
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/20 Novartis eye drug works with fewer injections than rival
06/15DJACTELION : J&J Maps Research Plans for Actelion -- WSJ
06/14DJACTELION : Correction to J&J Actelion Story
06/14DJACTELION : J&J Plans to Add Drug Discovery and Early Research to Actelion Unit
More sector news : Bio Therapeutic Drugs
Latest Tweets
06/22$OTIC: Otonomy successfully completes an end-of-phase 2 review with the FDA f..
1
06/22$OTIC (+0.0% pre) Otonomy Reports Successful End-of-Phase 2 Review by FDA for.. 
06/22Otonomy Announces Successful End-of-Phase 2 Review by FDA for OTIPRIO® in Acu.. 
06/22BRIEF-Otonomy announces successful end-of-phase 2 review by FDA for Otiprio  
06/22$OTIC Announces Successful End-of-Phase 2 Review by FDA for OTIPRIO in Acute ..
1
More tweets
Qtime:14
News from SeekingAlpha
06/13 OTONOMY : Thumbs Up Or Thumbs Down On This Niche Biotech Firm?
06/02 Premarket analyst action - healthcare
05/22 Otonomy (OTIC) Bank of America Merrill Lynch 2017 Health Care Conference - Sl..
05/06 Otonomy's (OTIC) CEO David Weber on Q1 2017 Results - Earnings Call Transcrip..
05/04 Otonomy misses by $0.03, beats on revenue
Advertisement
Chart OTONOMY INC
Duration : Period :
Otonomy Inc Technical Analysis Chart | OTIC | US68906L1052 | 4-Traders
Full-screen chart
Technical analysis trends OTONOMY INC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 33,8 $
Spread / Average Target 80%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
David A. Weber President, Chief Executive Officer & Director
Jay B. Lichter Chairman
Paul E. Cayer CFO, Chief Business & Principal Accounting Officer
Robert Michael Savel Chief Technical Officer
Dean Hakanson Chief Medical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
OTONOMY INC17.92%567
AMGEN17.98%126 856
CELGENE CORPORATION16.03%104 873
GILEAD SCIENCES-1.52%92 150
REGENERON PHARMACEUTIC..43.43%54 987
VERTEX PHARMACEUTICALS83.97%33 251
More Results